Full Text View
Tabular View
No Study Results Posted
Related Studies
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
This study is enrolling participants by invitation only.
Study NCT00666445   Information provided by Orasi Medical, Inc.
First Received: April 23, 2008   Last Updated: July 28, 2009   History of Changes

April 23, 2008
July 28, 2009
April 2008
February 2010   (final data collection date for primary outcome measure)
Sensitivity and specificity for test under investigation to diagnose probable Alzheimer's Disease. [ Time Frame: Immediately ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00666445 on ClinicalTrials.gov Archive Site
 
 
 
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: AD Template Development Study

This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria. Subjects diagnosed with Alzheimer's Disease as well as age-matched normal control subjects will be evaluated for symptoms of Alzheimer's Disease and those meeting inclusion criteria will undergo a brief, non-invasive scan of brain function using a magnetoencephalography (MEG). The scan itself lasts 1 minute while the subject is asked to stare at a dot projected in front of them on a video screen. Orasi Medical believes that patterns of brain activity measured at rest are indicative of Alzheimer's Disease pathology.

The protocol is amended to add a follow-up assessment for previously enrolled and completed subjects who agree to participate in the follow-up assessment approximately 9 - 15 months after initial study enrollment. Subjects who agree to participate in the follow-up assessment will undergo the same standardized tests and MEG scan procedure as completed in the initial study.

 
 
Observational
Case Control, Cross-Sectional
Alzheimer's Disease
 
  • Patients diagnosed with Alzheimer's Disease
  • Aged-matched normal controls
Georgopoulos AP, Karageorgiou E, Leuthold AC, Lewis SM, Lynch JK, Alonso AA, Aslam Z, Carpenter AF, Georgopoulos A, Hemmy LS, Koutlas IG, Langheim FJ, McCarten JR, McPherson SE, Pardo JV, Pardo PJ, Parry GJ, Rottunda SJ, Segal BM, Sponheim SR, Stanwyck JJ, Stephane M, Westermeyer JJ. Synchronous neural interactions assessed by magnetoencephalography: a functional biomarker for brain disorders. J Neural Eng. 2007 Dec;4(4):349-55. Epub 2007 Aug 27.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Enrolling by invitation
150
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject is between 18 and 90 years of age
  2. i. Provide written informed consent for study participation, OR ii. Provide written assent to study participant accompanied by the provision of written informed by the subject's legally authorized representative (LAR); see Section 8. Informed Consent for details of the procedures use to meet these study inclusion criteria
  3. Have one of the following clinical diagnoses or conditions:

    • Probable AD according to the NINCDS-ADRDA criteria
    • Possible AD according to the NINCDS-ADRDA criteria
    • Prodromal AD according to criteria described by Dubois & Albert (2004)
    • Normal control subject

Exclusion Criteria:

  1. Have a significant non-AD neurological condition including Parkinson's Disease, Vascular Dementia, Lewy Body Dementia or Frontal Temporal Dementia, human immunodeficiency virus, multiple sclerosis, epilepsy, or severe traumatic brain injury.
  2. Have dementia due to multiple etiologies (e.g. mixed dementia)
  3. Show the presence of prominent disturbances in gait thought to be associated with Parkinsonism.
  4. Show prominent changes in personality or social conduct prior to the onset of prominent cognitive dysfunction
  5. Have a Modified Hachinski Ischemia Scale score of greater than 4
  6. Have a history of primary psychotic disorder (e.g schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder
  7. Have a lifetime or current history of alcohol or substance abuse/dependence
  8. Have had an MRI two weeks prior to completing the MEG scan
  9. Have metal braces or pacemaker that may interfere with the MEG scan
  10. Are unable to complete the MEG scan procedure

Follow-up Assessment Inclusion Criteria:

Subjects who completed Protocol ADG 08-01 will be contacted and invited to participate in the follow-up assessment.

Both
18 Years to 90 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00666445
Todd Verdoorn, Ph.D., Chief Scientific Officer, Orasi Medical, Inc.
ADG-08-01
Orasi Medical, Inc.
  • Noran Neurology Clinic
  • Minneapolis Veterans Affairs Medical Center
Principal Investigator: Todd A Verdoorn, Ph.D. Orasi Medical, Inc.
Orasi Medical, Inc.
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP